GPCR Quote, Financials, Valuation and Earnings

Amgen has a net margin of -- compared to Structure Therapeutics's net margin of 21.23%. Structure Therapeutics's return on equity of -- beat Amgen's return on equity of 97.08%.

Structure Therapeutics has a consensus price target of $76.32, signalling upside risk potential of 216.03%. On the other hand Amgen has an analysts' consensus of $314.00 which suggests that it could grow by 15.72%. Given that Structure Therapeutics has higher upside potential than Amgen, analysts believe Structure Therapeutics is more attractive than Amgen.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.41% to investors and pays a quarterly dividend of $2.38 per share. Structure Therapeutics pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Amgen quarterly revenues of $8.1B. Structure Therapeutics's net income of -$46.8M is lower than Amgen's net income of $1.7B. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 24.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 4.30x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Structure Therapeutics's net margin of 21.68%. Structure Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Structure Therapeutics has a consensus price target of $76.32, signalling upside risk potential of 216.03%. On the other hand Eli Lilly and has an analysts' consensus of $966.01 which suggests that it could grow by 33.25%. Given that Structure Therapeutics has higher upside potential than Eli Lilly and, analysts believe Structure Therapeutics is more attractive than Eli Lilly and.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.77% to investors and pays a quarterly dividend of $1.50 per share. Structure Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Structure Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Structure Therapeutics's net income of -$46.8M is lower than Eli Lilly and's net income of $2.8B. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 58.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 13.36x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -- compared to Structure Therapeutics's net margin of 37.18%. Structure Therapeutics's return on equity of -- beat Novo Nordisk AS's return on equity of 84.88%.

Structure Therapeutics has a consensus price target of $76.32, signalling upside risk potential of 216.03%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 31.62%. Given that Structure Therapeutics has higher upside potential than Novo Nordisk AS, analysts believe Structure Therapeutics is more attractive than Novo Nordisk AS.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.37% to investors and pays a quarterly dividend of $1.10 per share. Structure Therapeutics pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Structure Therapeutics quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Structure Therapeutics's net income of -$46.8M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 20.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 6.97x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Viking Therapeutics's return on equity of --.

Structure Therapeutics has a consensus price target of $76.32, signalling upside risk potential of 216.03%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 231.24%. Given that Viking Therapeutics has higher upside potential than Structure Therapeutics, analysts believe Viking Therapeutics is more attractive than Structure Therapeutics.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Structure Therapeutics's net income of -$46.8M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.